SCHEMBL5482571

SCHEMBL5482571

CS(=O)(=O)Nc1ccc(C2(c3ccc(NS(C)(=O)=O)cc3)C(=O)Nc3oc(Cl)cc32)cc1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KIF11 P52732 1/20 0.40
TDP2 O95551 1/20 0.36
SMN1; SMN2 Q16637 2/20 0.36
ALDH1A1 P00352 2/20 0.36
HPGD P15428 2/20 0.36
KDM4E B2RXH2 1/20 0.36
LMNA P02545 1/20 0.36
HTT P42858 1/20 0.36
KEAP1 Q14145 1/20 0.35
CA12 O43570 1/20 0.35
CA1 P00915 1/20 0.35
CA2 P00918 1/20 0.35
CA9 Q16790 1/20 0.35
PGR P06401 2/20 0.34
MET P08581 1/20 0.34
GAA P10253 1/20 0.33
MAPK1 P28482 1/20 0.33
XDH P47989 1/20 0.33
EPHX2 P34913 1/20 0.33
PIP4K2A P48426 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5482166 0.78 CHRM2 (0.49) SMN1; SMN2ALDH1A1LMNAHTTKCNH2
SCHEMBL5481754 0.77 HTR6 (0.40) ALDH1A1HPGDKDM4ELMNAHTT
SCHEMBL5485549 0.74 KIF11 (0.40) KIF11TDP2SMN1; SMN2ALDH1A1HPGD
SCHEMBL5474271 0.74 KIF11 (0.40) KIF11TDP2SMN1; SMN2ALDH1A1HPGD
SCHEMBL5484218 0.73 KIF11 (0.42) KIF11TDP2SMN1; SMN2ALDH1A1HPGD
SCHEMBL5479295 0.71 KIF11 (0.40) KIF11HPGDKDM4ELMNAPGR
SCHEMBL5482310 0.69 SMN1; SMN2 (0.38) KIF11TDP2SMN1; SMN2ALDH1A1HPGD
SCHEMBL5478650 0.69 KIF11 (0.38) KIF11TDP2SMN1; SMN2ALDH1A1HPGD
SCHEMBL5480164 0.67 KIF11 (0.38) KIF11TDP2SMN1; SMN2ALDH1A1HPGD
SCHEMBL5478102 0.67 KEAP1 (0.38) KIF11TDP2SMN1; SMN2ALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070299102-A1 Diphenyl Ox-Indol-2-One Compounds and Their Use in the Treatment of Cancer TOPO TARGET A/S (DK) 2007-12-27 US claimed
US-20070299102-A1 Diphenyl Ox-Indol-2-One Compounds and Their Use in the Treatment of Cancer TOPO TARGET A/S (DK) 2007-12-27 US disclosed
EP-1734951-A2 DIPHENYL-INDOL-2-ON COMPOUNDS AND THEIR USE IN THE TREATMENT OF CANCER TopoTarget A/S (DK) 2006-12-27 EP disclosed
WO-2005097107-A2 DIPHENYL - INDOL-2-ON COMPOUNDS AND THEIR USE IN THE TREATMENT OF CANCER TOPOTARGET A/S (DK) 2005-10-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070299102-A1 Diphenyl Ox-Indol-2-One Compounds and Their Use in the Treatment of Cancer MTOR, RICTOR, CDK4 KIF11 4188/4885TDP2 3292/4885SMN1; SMN2 234/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.